WallStreetZenWallStreetZen

NASDAQ: CYCC
Cyclacel Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their CYCC stock forecasts and price targets.

Forecast return on equity

Is CYCC forecast to generate an efficient return?

Company
-2,378.77%
Industry
138.09%
Market
71.33%
CYCC's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CYCC forecast to generate an efficient return on assets?

Company
428.81%
Industry
22.7%
CYCC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CYCC earnings per share forecast

What is CYCC's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$1.95
Avg 2 year Forecast
-$1.18
Avg 3 year Forecast
-$1.12

CYCC revenue forecast

What is CYCC's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$50.0k-32.43%
Avg 2 year Forecast
$100.0k+35.14%
Avg 3 year Forecast
$100.0k+35.14%
CYCC's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CYCC revenue growth forecast

How is CYCC forecast to perform vs Biotechnology companies and vs the US market?

Company
13.55%
Industry
34.16%
Market
8.9%
CYCC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CYCC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CYCC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CYCC$0.40N/AN/A
DRMA$1.26$6.00+376.19%Strong Buy
ZVSA$1.02N/AN/A
NLSP$2.71N/AN/A
ENTO$0.50N/AN/A
View Top Biotech Stocks

Cyclacel Pharmaceuticals Stock Forecast FAQ

What is CYCC's earnings growth forecast for 2024-2026?

(NASDAQ: CYCC) Cyclacel Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.56%.

Cyclacel Pharmaceuticals's earnings in 2024 is -$13,481,000.On average, 1 Wall Street analyst forecast CYCC's earnings for 2024 to be -$12,260,050, with the lowest CYCC earnings forecast at -$12,260,050, and the highest CYCC earnings forecast at -$12,260,050. On average, 1 Wall Street analyst forecast CYCC's earnings for 2025 to be -$7,418,902, with the lowest CYCC earnings forecast at -$7,418,902, and the highest CYCC earnings forecast at -$7,418,902.

In 2026, CYCC is forecast to generate -$7,041,670 in earnings, with the lowest earnings forecast at -$7,041,670 and the highest earnings forecast at -$7,041,670.

If you're new to stock investing, here's how to buy Cyclacel Pharmaceuticals stock.

What is CYCC's revenue growth forecast for 2024-2026?

(NASDAQ: CYCC) Cyclacel Pharmaceuticals's forecast annual revenue growth rate of 13.55% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.16%, and while it is forecast to beat the US market's average forecast revenue growth rate of 8.9%.

Cyclacel Pharmaceuticals's revenue in 2024 is $74,000.On average, 1 Wall Street analysts forecast CYCC's revenue for 2024 to be $314,360, with the lowest CYCC revenue forecast at $314,360, and the highest CYCC revenue forecast at $314,360. On average, 1 Wall Street analysts forecast CYCC's revenue for 2025 to be $628,721, with the lowest CYCC revenue forecast at $628,721, and the highest CYCC revenue forecast at $628,721.

In 2026, CYCC is forecast to generate $628,721 in revenue, with the lowest revenue forecast at $628,721 and the highest revenue forecast at $628,721.

What is CYCC's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CYCC) forecast ROA is 428.81%, which is higher than the forecast US Biotechnology industry average of 22.7%.

What is CYCC's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: CYCC) Cyclacel Pharmaceuticals's current Earnings Per Share (EPS) is -$9.13. On average, analysts forecast that CYCC's EPS will be -$1.95 for 2024, with the lowest EPS forecast at -$1.95, and the highest EPS forecast at -$1.95. On average, analysts forecast that CYCC's EPS will be -$1.18 for 2025, with the lowest EPS forecast at -$1.18, and the highest EPS forecast at -$1.18. In 2026, CYCC's EPS is forecast to hit -$1.12 (min: -$1.12, max: -$1.12).

What is CYCC's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CYCC) forecast ROE is -2,378.77%, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.